Choline-SAM-GABA Dysregulation as a Unified Metabolic Framework Linking 

Cancer and Alzheimer's Disease Through Mirror Pathologies

ABSTRACT

Cancer and Alzheimer's disease (AD) demonstrate a robust inverse epidemiological 

relationship—cancer survivors show 33% reduced AD risk while AD patients exhibit 

69% lower cancer incidence. We propose that both diseases arise from a shared 

metabolic vulnerability rooted in simultaneous deficiency of ionotropic GABA_A 

and metabotropic GABA_B receptor systems, creating permissive conditions for 

either uncontrolled proliferation or autoimmune-like neurodegeneration. Central 

to this framework is the energetic equivalence between dual-GABA system 

dysfunction and impaired choline biosynthesis via S-adenosylmethionine (SAM)-

dependent phosphatidylethanolamine methylation. Both processes involve internal 

electron redistribution without net redox changes, creating metabolic constraint: 

cells cannot simultaneously maintain robust dual-GABA function and adequate 

SAM-dependent choline synthesis under resource limitation. This constraint leads 

to alpha-ketoglutarate dysregulation—accumulation disrupts alpha-ketoglutarate-

dependent dioxygenases controlling DNA/histone methylation, while circadian 

disruption creates temporal vulnerability windows. Cancer emerges when 

proliferative signaling proceeds without GABAergic inhibitory control; AD emerges 

when inflammatory responses cannot discharge externally and redirect as 

neurodegeneration. The framework explains the inverse relationship through mutual 

exclusivity: once one pathway activates, it consumes metabolic resources and 

actively inhibits the alternative. We present testable predictions and unified 

therapeutic strategies targeting choline-SAM metabolism, GABAergic restoration, 

and chronotherapeutic optimization.

KEYWORDS: cancer metabolism, Alzheimer's disease, choline biosynthesis, GABA 

receptors, S-adenosylmethionine, inverse epidemiology

1. INTRODUCTION

The Inverse Epidemiological Paradox and Shared Metabolic Abnormalities

Multiple independent epidemiological studies document a striking inverse 

relationship between cancer and Alzheimer's disease. Driver et al. reported that 

cancer survivors demonstrated 33% decreased AD risk while AD patients showed 69% 

lower cancer hospitalization risk (1). Meta-analyses confirm AD patients show 47% 

reduced overall cancer risk (RR: 0.53) while cancer patients demonstrate 39% 

reduced AD risk (RR: 0.61) (2). Autopsy studies validate this relationship even 

when controlling for diagnostic bias (3), suggesting genuine biological opposition 

rather than surveillance artifacts.

Despite their inverse occurrence, both diseases share striking metabolic 

abnormalities. Altered choline metabolism characterizes cancer—the "cholinic 

phenotype" of elevated phosphocholine observable across all tested cancer types 

reflects upregulated choline kinase and massive choline flux (4,5). AD demonstrates 

equally profound cholinergic abnormalities, with marked choline acetyltransferase 

decline and preferential basal forebrain cholinergic neuron degeneration (6,7). 

Both diseases show severe circadian disruption—shift work substantially elevates 

cancer risk (8,9) while AD demonstrates sundowning and sleep-wake cycle reversal 

(10). Alpha-ketoglutarate dysregulation links both: AD shows 50-75% KGDHC reduction 

(11,12), while cancer demonstrates profound α-KG disturbances through IDH mutations 

and altered TCA flux (13,14).

These parallel metabolic abnormalities in inversely-occurring diseases suggest a 

paradox: if both conditions share common metabolic vulnerabilities, why do they 

show inverse epidemiology? We hypothesize that this reflects mutually exclusive 

failure modes of shared underlying metabolic constraint.

Figure 1 The Choline-SAM-GABA Dysregulation as a Unified Metabolic Framework Linking Cancer and Alzheimer's Disease.

The inverse epidemiological relationship between cancer and AD reflects mutually exclusive failure modes of a shared metabolic constraint. The constraint originates from the energetic equivalence between dual-GABA (GABA – a and GABA – b)deficiency and impaired SAM-choline synthesis. This vulnerability leads to shared alpha-ketoglutarate dysregulation. The final disease outcome is determined by distinct stress-response pathways: the Epinephrine-mediated pathway (blue arrow) drives cancer proliferation by overcoming GABAergic inhibition, while the Vasopressin-mediated pathway (red arrow) drives Alzheimer's neurodegeneration through redirected inflammatory responses . Once activated, the demands of one pathway actively prevent the activation of the alternative .

2. THE HYPOTHESIS: ENERGETIC EQUIVALENCE AND METABOLIC CONSTRAINT

2.1 The Central Proposition: Energetic Equivalence

We propose that simultaneous deficiency in both ionotropic GABA_A and metabotropic 

GABA_B receptor systems is energetically equivalent to impaired choline biosynthesis 

via SAM-dependent pathways. This equivalence creates a fundamental metabolic 

constraint that predisposes to either cancer or AD depending on which stress-

response pathways subsequently activate.

The mechanistic basis involves energetic signatures. SAM-dependent choline 

synthesis—sequential methylation of phosphatidylethanolamine to phosphatidylcholine 

via PEMT—consumes three SAM molecules per choline through pure methylation reactions 

without external electron exchange (15,16). In hepatocytes, approximately 30% of 

phosphatidylcholine synthesis proceeds through PEMT (17). Critically, each 

methylation involves only internal electron redistribution without net redox 

changes—no NAD+/NADH interconversion, no FAD/FADH2 cycling, no oxygen utilization 

(18).

GABA receptor-mediated regulatory processes share this energetic characteristic. 

GABA_A receptor activation produces chloride flux—pure ionic redistribution without 

redox chemistry (19). GABA_B receptor signaling modulates enzyme activities through 

G-protein-mediated conformational changes and phosphorylation cascades, again 

involving charge redistribution rather than oxidation-reduction (20,21). The 

coordinated regulation of GABA synthesis, release, and metabolic integration 

operates through electrochemical gradients rather than redox reactions (22).

This energetic equivalence creates metabolic constraint: our hypothesis predicts 

that cells cannot simultaneously maintain robust dual-GABA receptor function and 

adequate SAM-dependent choline synthesis when metabolic resources become limiting. 

Both processes compete for cellular energy allocation toward non-redox regulatory 

mechanisms. When energy must be redirected toward oxidative metabolism (TCA cycle, 

oxidative phosphorylation), processes operating through internal electron 

redistribution become compromised.

2.2 Alpha-Ketoglutarate Dysregulation as the Metabolic Consequence

The GABA shunt—an alternative TCA cycle pathway bypassing KGDHC—involves glutamate 

decarboxylation to GABA followed by GABA transamination with α-ketoglutarate, 

producing succinate semialdehyde and regenerating glutamate (23,24). We hypothesize 

that functional dual-GABA receptor systems regulate this metabolic process, thereby 

influencing α-KG homeostasis. Deficiency in dual-GABA receptor function would 

disrupt this regulation through: altered glutamate/GABA balance affecting GABA-T 

substrate availability; impaired coordination between GABA synthesis and catabolism; 

and loss of GABA receptor-mediated metabolic signaling that normally adjusts enzyme 

activities to metabolic demands.

If this hypothesis is correct, dual-GABA deficiency would create conditions 

permitting α-KG accumulation—not through simple failure to "consume" α-KG but 

through loss of coordinated metabolic regulation. This prediction aligns with 

observed α-KG dysregulation in both diseases: marked KGDHC deficiency in AD (11,12) 

and α-KG perturbations in cancer through IDH mutations producing 2-hydroxyglutarate 

(13,14).

Accumulated α-KG would disrupt α-KG-dependent dioxygenases controlling DNA and 

histone methylation—TET enzymes and JmjC-domain demethylases (25,26). The balance 

between SAM-dependent methylation (which we hypothesize is impaired due to energetic 

equivalence with dual-GABA deficiency) and α-KG-dependent demethylation (which we 

propose becomes hyperactive due to α-KG accumulation) determines epigenetic 

landscapes. This framework offers a potential explanation for the paradoxical 

methylation patterns in both diseases: cancer shows global DNA hypomethylation with 

regional CpG island hypermethylation (27), while AD demonstrates altered histone 

methylation affecting tau processing (28).

2.3 Circadian Vulnerability and "Darkness Stress"

Both SAM synthesis and GABA synthesis show circadian oscillation (29,30). 

Metabotropic GABA_B receptors contribute to circadian metabolic entrainment through 

sustained G-protein signaling modulating cAMP and CREB phosphorylation, thereby 

affecting circadian gene expression (31). The suprachiasmatic nucleus shows dense 

GABAergic innervation with GABA mediating communication between SCN neurons (32).

We hypothesize that GABA_B deficiency creates "darkness stress"—nocturnal metabolic 

dysregulation occurring when compensatory mechanisms functioning during daylight fail 

during dark periods. This prediction aligns with observed circadian disruption in 

both diseases: shift work substantially elevates cancer risk (8,9), while AD 

demonstrates sundowning and sleep-wake cycle abnormalities (10). Melatonin—the 

primary circadian hormone—shows reduced production in both conditions (33,34).

The convergence of α-KG dysregulation ("cold stress") and circadian dysregulation 

("darkness stress") during nighttime would create maximum vulnerability windows. DNA 

repair shows circadian oscillation with efficiency peaking mid-day and reaching 

nadir at night (35). If our hypothesis is correct, dual-GABA deficiency would 

disrupt these protective oscillations, leaving cells vulnerable throughout extended 

periods.

2.4 Disease-Specific Manifestations: Cancer vs. AD

Given shared metabolic vulnerability (dual-GABA deficiency with impaired SAM-

dependent choline synthesis), we hypothesize that disease-specific outcomes depend 

on which stress-response pathways subsequently activate.

Cancer pathway: We propose cancer emerges when epinephrine-mediated proliferative 

stress responses proceed without GABAergic inhibitory control. Cancer cells 

demonstrate the "cholinic phenotype"—elevated phosphocholine and upregulated choline 

kinase—which we interpret as metabolic compensation for deficient SAM-dependent 

choline synthesis (4,5). Upregulating the Kennedy pathway (choline phosphorylation 

to phosphocholine) and choline scavenging provides a workaround analogous to 

organisms developing auxotrophy for nutrients they cannot synthesize. This framework 

predicts that cancer cells' altered choline metabolism reflects not simple increased 

membrane demand but fundamental disruption of the SAM-GABA energetic balance.

AD pathway: We hypothesize AD emerges when vasopressin-mediated inflammatory 

responses cannot discharge externally and redirect as neurodegeneration. Basal 

forebrain cholinergic neurons show particular vulnerability, which we attribute to 

their unique metabolic demands: continuous high-rate acetylcholine synthesis 

requiring sustained choline availability (36,37). Under dual-GABA deficiency 

(energetically equivalent to impaired choline synthesis capacity), these neurons 

face a double constraint: reduced synthesis capability when demands remain highest, 

plus impaired inhibitory regulation increasing metabolic demands through 

hyperexcitability.

The failure of simple choline supplementation to modify AD progression (38) supports 

our framework: if the fundamental problem involves impaired SAM-dependent synthesis 

capacity rather than substrate deficiency, providing exogenous choline via the 

Kennedy pathway offers only partial compensation while the energetic constraint 

persists.

2.5 The Inverse Relationship: Mutual Exclusivity

We hypothesize the inverse epidemiological relationship reflects mutual exclusivity 

at the metabolic level. Both diseases require the same underlying vulnerability 

(dual-GABA deficiency with impaired choline synthesis), but once one pathway 

activates and dominates, it consumes metabolic resources and actively inhibits the 

alternative pathway.

This framework predicts: (1) individuals with robust dual-GABA function maintain 

both SAM-dependent choline synthesis and proper α-KG regulation, showing reduced 

risk for both diseases; (2) individuals with dual-GABA deficiency become vulnerable 

to both but typically manifest only one; (3) which disease manifests depends on 

which stress-response system activates first; (4) once activated, that pathway's 

metabolic demands prevent the alternative pathway from activating.

If correct, this hypothesis offers testable predictions about genetic risk factors, 

biomarkers indicating pre-disease vulnerability, and therapeutic interventions 

targeting the shared metabolic constraint.

3. EVALUATION OF THE HYPOTHESIS

3.1 Supporting Evidence

Several lines of evidence support this framework:

Energetic considerations: The non-redox character of both SAM-dependent methylation 

and certain GABA regulatory processes is biochemically established (15,18-22). That 

processes sharing energetic signatures compete when resources become limiting 

represents fundamental bioenergetic principle.

Choline metabolism patterns: The cholinic phenotype in cancer (4,5) and cholinergic 

collapse in AD (6,7) are well-documented. Our framework offers a unifying 

explanation: both reflect consequences of impaired SAM-dependent synthesis capacity, 

with compensatory responses differing based on disease context.

Alpha-KG dysregulation: KGDHC deficiency in AD (11,12) and α-KG perturbations in 

cancer (13,14) are among the most consistent metabolic findings in these diseases. 

The GABA shunt's role in α-KG metabolism (23,24) provides a mechanistic link between 

GABA dysfunction and α-KG dysregulation.

Circadian disruption: The profound circadian abnormalities in both diseases (8-10, 

33,34) align with our prediction that GABA_B deficiency disrupts circadian metabolic 

entrainment. Melatonin's therapeutic promise in both conditions (though with 

different optimal timing) supports shared circadian vulnerability manifesting through 

different temporal patterns.

GABA systems in both diseases: GABA receptor expression abnormalities have been 

documented in both cancer (39) and AD (40), though often interpreted within disease-

specific frameworks rather than as manifestations of shared vulnerability.

Genetic susceptibility: PEMT polymorphisms affect choline synthesis capacity and 

disease susceptibility (41,42). If our hypothesis is correct, we would predict that 

PEMT variants interact with GABAergic system genetics to determine disease risk.

3.2 Challenging Evidence and Alternative Explanations

Several observations require careful consideration:

Complexity of mechanisms: Both cancer and AD involve multifactorial pathogenesis. 

Our framework proposes a metabolic constraint creating permissiveness, not a single 

causal mechanism. Multiple additional factors (genetic, environmental, stochastic) 

determine whether and which disease manifests.

GABA shunt quantitative significance: While the GABA shunt can account for 10-40% of 

glucose-derived TCA cycle carbon in specific brain regions (43), its quantitative 

impact on whole-organism α-KG homeostasis requires further characterization. Our 

hypothesis predicts regulatory importance rather than necessarily quantitative 

dominance.

Specificity questions: Why would dual-GABA deficiency specifically predispose to 

cancer and AD rather than other diseases? We hypothesize these conditions reflect 

extreme manifestations—uncontrolled proliferation vs. progressive neurodegeneration—

of metabolic failure modes that may have subclinical manifestations in other 

contexts.

Therapeutic paradoxes: If the diseases share underlying vulnerability, why don't 

interventions effective in one help the other? We propose this reflects disease-

stage differences: early intervention targeting the shared vulnerability might 

prevent both, while late intervention after disease-specific pathology emerges 

requires disease-specific approaches.

Alternative frameworks: Other hypotheses for the inverse relationship include 

antagonistic pleiotropy (genes beneficial for one condition harmful for the other) 

(44), p53 activity differences (45), and PIN1 dysregulation (46). Our framework is 

compatible with these mechanisms operating downstream or in parallel with the 

fundamental metabolic constraint we propose.

3.3 Critical Assumptions Requiring Validation

This hypothesis makes several critical assumptions requiring experimental validation:

1. That dual-GABA deficiency (both A and B receptor systems) creates different 

pathophysiology than single-receptor deficiency

2. That the energetic equivalence between SAM-dependent processes and certain GABA 

regulatory functions creates actual competition under metabolic constraint

3. That α-KG accumulation resulting from dysregulated GABA shunt function 

significantly impacts dioxygenase activity

4. That circadian GABA_B function plays the regulatory role we propose

5. That stress-response pathway selection (epinephrine vs. vasopressin) determines 

disease outcome in vulnerable individuals

4. TESTABLE PREDICTIONS AND THERAPEUTIC IMPLICATIONS

4.1 Specific Testable Predictions

This framework generates several experimentally testable predictions:

1. Genetic prediction: Individuals carrying specific combinations of PEMT variants 

(reducing SAM-dependent choline synthesis capacity) and GABA receptor variants 

(reducing dual-GABA function) should show elevated risk for either cancer or AD, 

with higher combined risk than expected from additive effects alone.

2. Biomarker prediction: Individuals with dual-GABA deficiency should show: (a) 

altered SAM/SAH ratios, (b) abnormal phosphatidylcholine/phosphatidylethanolamine 

ratios, (c) elevated α-KG levels, (d) specific circadian rhythm abnormalities, (e) 

altered methylation patterns, detectable before overt disease.

3. Energetic prediction: Experimental metabolic constraint (limiting substrates for 

SAM synthesis or ATP availability) should produce greater impairment in cells with 

pre-existing GABA receptor deficiency than in control cells, specifically affecting 

SAM-dependent processes.

4. Circadian prediction: The magnitude of nighttime α-KG dysregulation should 

correlate with GABA_B receptor function, with deficiency producing specific patterns 

of nocturnal metabolic abnormality.

5. Therapeutic prediction: Interventions supporting both SAM-dependent choline 

synthesis (SAM or betaine supplementation) and GABAergic function (GABA_B agonists) 

should show synergistic effects in preventing or slowing disease progression, 

superior to either intervention alone.

6. Inverse relationship prediction: In populations with high cancer incidence, 

subgroups with specific GABA receptor genotypes should show lower AD incidence, and 

vice versa, beyond the population-level inverse relationship.

4.2 Therapeutic Implications

If this hypothesis is validated, it suggests several therapeutic strategies:

Primary prevention: Individuals identified through genetic or biomarker screening as 

having dual-GABA deficiency with impaired SAM-dependent choline synthesis could 

receive: (a) optimized choline/betaine/SAM supplementation, (b) GABAergic support 

through lifestyle (meditation, yoga) or pharmacological approaches, (c) circadian 

optimization, (d) stress-response modulation.

Secondary prevention: For individuals showing early metabolic abnormalities (elevated 

α-KG, altered methylation patterns, circadian disruption) without overt disease: (a) 

intensive metabolic support targeting the choline-SAM-GABA axis, (b) chronotherapeutic 

interventions optimizing medication timing, (c) monitoring for early disease 

manifestations enabling rapid intervention.

Disease modification: Even after disease onset, interventions targeting the underlying 

metabolic constraint might slow progression: (a) combination therapies addressing 

multiple pathway components, (b) chronotherapy optimizing timing of interventions, 

(c) personalized approaches based on individual metabolic profiles.

4.3 Limitations and Future Directions

This hypothesis faces several limitations requiring future work:

The energetic equivalence concept, while biochemically grounded, requires direct 

experimental validation demonstrating competition between SAM-dependent processes 

and GABA regulatory functions under metabolic constraint. The quantitative 

relationships between GABA shunt activity, α-KG accumulation, and dioxygenase 

dysfunction need characterization. The mechanisms determining which stress-response 

pathway (cancer vs. AD) activates in vulnerable individuals remain incompletely 

specified.

Future studies should: (1) test genetic predictions through large-scale association 

studies examining PEMT-GABA receptor interactions; (2) validate biomarker predictions 

in prospective cohorts; (3) perform mechanistic studies in model systems testing 

energetic competition predictions; (4) conduct clinical trials of combination 

interventions targeting the choline-SAM-GABA axis.

5. CONCLUSIONS

We propose that the inverse relationship between cancer and Alzheimer's disease 

reflects mutually exclusive failure modes of shared metabolic vulnerability: 

simultaneous deficiency in dual-GABA receptor systems (both ionotropic GABA_A and 

metabotropic GABA_B), energetically equivalent to impaired SAM-dependent choline 

biosynthesis. This creates a metabolic constraint characterized by α-ketoglutarate 

dysregulation and circadian disruption. Cancer emerges when proliferative signaling 

proceeds without GABAergic inhibition; AD emerges when inflammatory responses 

redirect as neurodegeneration. The inverse epidemiology reflects mutual exclusivity: 

once one pathway dominates, it consumes resources preventing alternative pathway 

activation.

This framework unifies disparate observations—the cholinic phenotype in cancer, 

cholinergic collapse in AD, KGDHC deficiency in AD, IDH mutations in cancer, 

circadian disruption in both—under a single organizing principle. It generates 

testable predictions regarding genetics, biomarkers, and therapeutic interventions. 

If validated, it suggests that addressing the shared metabolic vulnerability through 

combination therapies targeting choline-SAM metabolism, GABAergic restoration, and 

circadian optimization might prevent or slow progression of both diseases.

The hypothesis acknowledges substantial uncertainty and requires rigorous experimental 

testing. However, by offering a mechanistic explanation for the robust inverse 

epidemiological relationship and providing testable predictions, it establishes a 

framework for future investigation into the metabolic basis of two major age-related 

diseases.

Author Information

IL WOONG CHOIIndependent Researcher, OXFORD, UKEmail: iwchoikr@gmail.comORCID: 0009-0004-1292-0610

Funding

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Competing Interests

The author declares no competing interests.

Ethics Approval

Not applicable.

Data Availability

Not applicable - no datasets were generated or analyzed during this study.

Declaration of generative AI and AI-assisted technologies in the manuscript preparation process 

During the preparation of this work the author(s) used Claude (Anthropic) in order to improve language clarity, refine manuscript structure, and verify reference formatting. After using this tool, the author(s) reviewed and edited the content as needed and take(s) full responsibility for the content of the published article.

REFERENCES

1. Driver JA, Beiser A, Au R, et al. Inverse association between cancer and 

Alzheimer's disease: results from the Framingham Heart Study. BMJ. 2012;344:e1442.

2. Shi HB, Tang B, Liu YW, Wang XF, Chen GJ. Alzheimer disease and cancer risk: a 

meta-analysis. J Cancer Res Clin Oncol. 2015;141(3):485-494.

3. Roe CM, Behrens MI, Xiong C, Miller JP, Morris JC. Alzheimer disease and cancer. 

Neurology. 2005;64(5):895-898.

4. Glunde K, Bhujwalla ZM, Ronen SM. Choline metabolism in malignant transformation. 

Nat Rev Cancer. 2011;11(12):835-848.

5. Podo F, Canevari S, Canese R, Pisanu ME, Ricci A, Iorio E. MR evaluation of 

response to targeted treatment in cancer cells. NMR Biomed. 2011;24(6):648-672.

6. Bartus RT, Dean RL 3rd, Beer B, Lippa AS. The cholinergic hypothesis of geriatric 

memory dysfunction. Science. 1982;217(4558):408-414.

7. Perry EK, Perry RH, Blessed G, Tomlinson BE. Changes in brain cholinesterases in 

senile dementia of Alzheimer type. Neuropathol Appl Neurobiol. 1978;4(4):273-277.

8. Straif K, Baan R, Grosse Y, et al. Carcinogenicity of shift-work, painting, and 

fire-fighting. Lancet Oncol. 2007;8(12):1065-1066.

9. Stevens RG, Brainard GC, Blask DE, Lockley SW, Motta ME. Breast cancer and 

circadian disruption from electric lighting in the modern world. CA Cancer J Clin. 

2014;64(3):207-218.

10. Musiek ES, Xiong DD, Holtzman DM. Sleep, circadian rhythms, and the pathogenesis 

of Alzheimer disease. Exp Mol Med. 2015;47:e148.

11. Gibson GE, Starkov A, Blass JP, Ratan RR, Beal MF. Cause and consequence: 

mitochondrial dysfunction initiates and propagates neuronal dysfunction, neuronal 

death and behavioral abnormalities in age-associated neurodegenerative diseases. 

Biochim Biophys Acta. 2010;1802(1):122-134.

12. Bubber P, Haroutunian V, Fisch G, Blass JP, Gibson GE. Mitochondrial abnormalities 

in Alzheimer brain: mechanistic implications. Ann Neurol. 2005;57(5):695-703.

13. Dang L, White DW, Gross S, et al. Cancer-associated IDH1 mutations produce 

2-hydroxyglutarate. Nature. 2009;462(7274):739-744.

14. Xu W, Yang H, Liu Y, et al. Oncometabolite 2-hydroxyglutarate is a competitive 

inhibitor of α-ketoglutarate-dependent dioxygenases. Cancer Cell. 2011;19(1):17-30.

15. Vance DE, Ridgway ND. The methylation of phosphatidylethanolamine. Prog Lipid 

Res. 1988;27(1):61-79.

16. Zeisel SH, Blusztajn JK. Choline and human nutrition. Annu Rev Nutr. 1994;14:269-296.

17. DeLong CJ, Shen YJ, Thomas MJ, Cui Z. Molecular distinction of phosphatidylcholine 

synthesis between the CDP-choline pathway and phosphatidylethanolamine methylation 

pathway. J Biol Chem. 1999;274(42):29683-29688.

18. Fontecave M, Atta M, Mulliez E. S-adenosylmethionine: nothing goes to waste. 

Trends Biochem Sci. 2004;29(5):243-249.

19. Sieghart W, Savić MM. International Union of Basic and Clinical Pharmacology. 

CVI: GABA_A receptor subtype- and function-selective ligands: key issues in 

translation to humans. Pharmacol Rev. 2018;70(4):836-878.

20. Bettler B, Kaupmann K, Mosbacher J, Gassmann M. Molecular structure and 

physiological functions of GABA_B receptors. Physiol Rev. 2004;84(3):835-867.

21. Gassmann M, Bettler B. Regulation of neuronal GABA_B receptor functions by 

subunit composition. Nat Rev Neurosci. 2012;13(6):380-394.

22. Waagepetersen HS, Sonnewald U, Schousboe A. The GABA paradox: multiple roles as 

metabolite, neurotransmitter, and neurodifferentiative agent. J Neurochem. 

1999;73(4):1335-1342.

23. Schousboe A, Bak LK, Waagepetersen HS. Astrocytic control of biosynthesis and 

turnover of the neurotransmitters glutamate and GABA. Front Endocrinol (Lausanne). 

2013;4:102.

24. Petroff OA. GABA and glutamate in the human brain. Neuroscientist. 2002;8(6):562-573.

25. Tahiliani M, Koh KP, Shen Y, et al. Conversion of 5-methylcytosine to 

5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science. 

2009;324(5929):930-935.

26. Kooistra SM, Helin K. Molecular mechanisms and potential functions of histone 

demethylases. Nat Rev Mol Cell Biol. 2012;13(5):297-311.

27. Ehrlich M. DNA hypomethylation in cancer cells. Epigenomics. 2009;1(2):239-259.

28. Lithner CU, Lacor PN, Zhao WQ, et al. Disruption of neocortical histone H3 

homeostasis by soluble Aβ: implications for Alzheimer's disease. Neurobiol Aging. 

2013;34(9):2081-2090.

29. Nakahata Y, Sahar S, Astarita G, Kaluzova M, Sassone-Corsi P. Circadian control 

of the NAD+ salvage pathway by CLOCK-SIRT1. Science. 2009;324(5927):654-657.

30. Gerstner JR, Lyons LC, Wright KP Jr, et al. Cycling behavior and memory 

formation. J Neurosci. 2009;29(41):12824-12830.

31. Aton SJ, Colwell CS, Harmar AJ, Waschek J, Herzog ED. Vasoactive intestinal 

polypeptide mediates circadian rhythmicity and synchrony in mammalian clock neurons. 

Nat Neurosci. 2005;8(4):476-483.

32. Moore RY, Speh JC. GABA is the principal neurotransmitter of the circadian 

system. Neurosci Lett. 1993;150(2):112-116.

33. Blask DE, Dauchy RT, Sauer LA. Putting cancer to sleep at night: the 

neuroendocrine/circadian melatonin signal. Endocrine. 2005;27(2):179-188.

34. Wu YH, Swaab DF. Disturbance and strategies for reactivation of the circadian 

rhythm system in aging and Alzheimer's disease. Sleep Med. 2007;8(6):623-636.

35. Kang TH, Reardon JT, Kemp M, Sancar A. Circadian oscillation of nucleotide 

excision repair in mammalian brain. Proc Natl Acad Sci USA. 2009;106(8):2864-2867.

36. Sarter M, Parikh V. Choline transporters, cholinergic transmission and cognition. 

Nat Rev Neurosci. 2005;6(1):48-56.

37. Mesulam MM, Mufson EJ, Levey AI, Wainer BH. Cholinergic innervation of cortex by 

the basal forebrain: cytochemistry and cortical connections of the septal area, 

diagonal band nuclei, nucleus basalis (substantia innominata), and hypothalamus in 

the rhesus monkey. J Comp Neurol. 1983;214(2):170-197.

38. Ylilauri MP, Voutilainen S, Lönnroos E, et al. Association of dietary choline 

intake with risk of incident dementia and with cognitive performance: the Kuopio 

Ischaemic Heart Disease Risk Factor Study. Am J Clin Nutr. 2019;110(6):1416-1423.

39. Schuller HM, Al-Wadei HA, Majidi M. GABA B receptor is a novel drug target for 

pancreatic cancer. Cancer. 2008;112(4):767-778.

40. Rissman RA, De Blas AL, Armstrong DM. GABA_A receptors in aging and Alzheimer's 

disease. J Neurochem. 2007;103(4):1285-1292.

41. da Costa KA, Kozyreva OG, Song J, Galanko JA, Fischer LM, Zeisel SH. Common 

genetic polymorphisms affect the human requirement for the nutrient choline. FASEB 

J. 2006;20(9):1336-1344.

42. Kohlmeier M, da Costa KA, Fischer LM, Zeisel SH. Genetic variation of folate-

mediated one-carbon transfer pathway predicts susceptibility to choline deficiency 

in humans. Proc Natl Acad Sci USA. 2005;102(44):16025-16030.

43. Rothman DL, Behar KL, Hyder F, Shulman RG. In vivo NMR studies of the glutamate 

neurotransmitter flux and neuroenergetics: implications for brain function. Annu Rev 

Physiol. 2003;65:401-427.

44. Campisi J. Aging, cellular senescence, and cancer. Annu Rev Physiol. 2013;75:685-705.

45. Levine AJ, Jenkins NA, Copeland NG. The roles of initiating truncal mutations in 

human cancers: the order of mutations and tumor cell type matters. Cancer Cell. 

2019;35(1):10-15.

46. Driver JA, Lu KP. PIN1: a new genetic link between Alzheimer's disease, cancer 

and aging. Curr Aging Sci. 2010;3(3):158-165.